Emmanuel S. Antonarakis, MD

Articles

Drs Antonarakis and Jha on Extending Clinical Trials to the Community Setting

April 3rd 2024

Emmanuel Antonarakis, MD, and Gautam Jha, MD, on collaboration efforts extending the reach of clinical trials beyond university hospitals.

Dr Antonarakis on Community Enrollment in the ECLIPSE Trial in Prostate Cancer

March 29th 2024

Emmanuel Antonarakis, MD, discusses community enrollment in the ECLIPSE trial in prostate cancer.

Drs Jha and Antonarakis on Collaboration Between Community and Academic Oncologists

March 29th 2024

Gautam Jha, MD, and Emmanuel Antonarakis, MD, on the advantages of collaborative efforts between community and academic oncologists.

Dr Antonarakis on Early Intervention With PARP Inhibitors in mHSPC

March 20th 2024

Emmanuel Antonarakis, MD, discusses the significance of TALPRO-3, EVOPAR, and AMPLITUDE trials on the metastatic prostate cancer treatment paradigm.

Dr. Antonarakis on the Benefits of Genetic Testing for Select Patients With Prostate Cancer

November 14th 2022

Emmanuel Antonarakis, MD, discusses the benefits of somatic and germline testing for patients with prostate cancer.

Dr. Antonarakis on Therapeutic Agents for Select Patients With mCRPC

November 11th 2022

Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.

Dr. Antonarakis on Implications of an MMR Deficiency in Prostate Cancer

April 18th 2019

Emmanuel S. Antonarakis, MD, associate professor of oncology, Johns Hopkins University, discusses the clinical implications of an MMR deficiency in patients with prostate cancer.